Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPKATO, KenAJANI, Jaffer A.DOKI, YuichiroXU, JianmingWYRWICZ, LucjanMOTOYAMA, SatoruOGATA, TakashiKAWAKAMI, HisatoHSU, Chih-HungADENIS, AntoineHAJBI, Farid ElBARTOLOMEO, Maria DiBRAGHIROLI, Maria Ignez Freitas MelroHOLTVED, EvaMURPHY, Mariela A. BlumPATEL, ApurvaHU, NanMATSUMURA, YasuhiroCHAU, IanKITAGAWA, Yuko2024-03-082024-03-082023JOURNAL OF CLINICAL ONCOLOGY, v.41, suppl.4, p.290-290, 20230732-183Xhttps://observatorio.fm.usp.br/handle/OPI/58518engrestrictedAccessNivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.conferenceObjectCopyright LIPPINCOTT WILLIAMS & WILKINSOncology1527-7755